MCID: ANL017
MIFTS: 51

Anal Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 15 17 74
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 51 C9161

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and in situ carcinoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Immunologic Factors and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.1 AKT1 CDKN2A PIK3CA TP53
2 in situ carcinoma 30.7 CDKN2A TP53
3 squamous cell papilloma 30.6 CDKN2A TP53
4 cervix carcinoma 30.5 CDKN2A TP53
5 suppressor of tumorigenicity 3 30.4 CDKN2A TP53
6 adenocarcinoma 28.8 AKT1 APC CDKN2A MLH1 PIK3CA TP53
7 inverted papilloma 10.4 CDKN2A TP53
8 bladder squamous cell carcinoma 10.3 CDKN2A TP53
9 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
10 spitz nevus 10.3 CDKN2A TP53
11 bladder carcinoma in situ 10.3 CDKN2A TP53
12 vulva squamous cell carcinoma 10.3 CDKN2A TP53
13 scrotal carcinoma 10.3 CDKN2A TP53
14 vulvar disease 10.3 CDKN2A TP53
15 nasal cavity adenocarcinoma 10.3 CDKN2A TP53
16 bartholin's gland disease 10.3 CDKN2A TP53
17 megaesophagus 10.3 CDKN2A TP53
18 keratoacanthoma 10.3 MLH1 TP53
19 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A TP53
20 gastric adenosquamous carcinoma 10.3 CDKN2A TP53
21 anogenital venereal wart 10.3 CDKN2A TP53
22 cervix uteri carcinoma in situ 10.3 CDKN2A TP53
23 uterus carcinoma in situ 10.3 CDKN2A TP53
24 oral leukoplakia 10.3 CDKN2A TP53
25 hyperplastic polyposis syndrome 10.3 APC TP53
26 meningeal melanomatosis 10.3 CDKN2A TP53
27 mutyh-associated polyposis 10.3 APC TP53
28 endocervical adenocarcinoma 10.3 CDKN2A TP53
29 penile disease 10.3 CDKN2A TP53
30 ovarian clear cell carcinoma 10.3 PIK3CA TP53
31 cervix small cell carcinoma 10.3 CDKN2A TP53
32 necrotizing sialometaplasia 10.3 CDKN2A TP53
33 basaloid squamous cell carcinoma 10.2 CDKN2A TP53
34 polyposis syndrome, hereditary mixed, 1 10.2 APC MLH1
35 tongue disease 10.2 CDKN2A TP53
36 adult hepatocellular carcinoma 10.2 PIK3CA TP53
37 malignant spiradenoma 10.2 PIK3CA TP53
38 optic nerve neoplasm 10.2 CDKN2A TP53
39 papilloma 10.2
40 juvenile pilocytic astrocytoma 10.2 CDKN2A TP53
41 uterine corpus serous adenocarcinoma 10.2 PIK3CA TP53
42 breast squamous cell carcinoma 10.2 PIK3CA TP53
43 tonsil cancer 10.2 CDKN2A TP53
44 uterine body mixed cancer 10.2 PIK3CA TP53
45 pre-malignant neoplasm 10.2 CDKN2A TP53
46 vulva cancer 10.2 CDKN2A TP53
47 richter's syndrome 10.2 MLH1 TP53
48 uterine corpus cancer 10.2 PIK3CA TP53
49 ulcerative stomatitis 10.2 TP53 TP73
50 dermatitis 10.1

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.62 AKT1 CDKN2A MLH1 TP53 TP73
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.62 AKT1 CDKN2A MLH1 TP53 TP73
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.26 MDM2 MLH1 TP53 TP73

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

47 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.19 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
2 endocrine/exocrine gland MP:0005379 10.17 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
3 behavior/neurological MP:0005386 10.15 AKT1 APC CDKN2A MDM2 PIK3CA TP53
4 cardiovascular system MP:0005385 10.14 AKT1 APC CDKN2A MDM2 PIK3CA TP53
5 homeostasis/metabolism MP:0005376 10.14 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
6 immune system MP:0005387 10.13 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
7 embryo MP:0005380 10.12 AKT1 APC CDKN2A MDM2 PIK3CA TP53
8 growth/size/body region MP:0005378 10.1 AKT1 APC CDKN2A MDM2 PIK3CA TP53
9 hematopoietic system MP:0005397 10.09 AKT1 APC CDKN2A MDM2 MLH1 TP53
10 mortality/aging MP:0010768 10.08 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
11 digestive/alimentary MP:0005381 10.06 APC CDKN2A MDM2 MLH1 TP53 TP73
12 integument MP:0010771 10.05 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
13 neoplasm MP:0002006 10.03 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
14 nervous system MP:0003631 9.95 AKT1 APC CDKN2A MDM2 PIK3CA TP53
15 muscle MP:0005369 9.93 AKT1 APC CDKN2A MDM2 PIK3CA TP53
16 liver/biliary system MP:0005370 9.89 AKT1 APC CDKN2A MDM2 TP53
17 reproductive system MP:0005389 9.86 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
18 no phenotypic analysis MP:0003012 9.67 CDKN2A MDM2 PIK3CA TP53
19 pigmentation MP:0001186 9.62 APC CDKN2A MDM2 TP53
20 respiratory system MP:0005388 9.55 AKT1 CDKN2A MLH1 TP53 TP73
21 skeleton MP:0005390 9.5 AKT1 APC CDKN2A MDM2 PIK3CA TP53
22 vision/eye MP:0005391 9.1 APC CDKN2A MLH1 PIK3CA TP53 TP73

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
5
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
6 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
7 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
9 Albumin-Bound Paclitaxel Phase 3,Phase 2
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
11 Antimitotic Agents Phase 3,Phase 2
12 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
13 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
15 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
17
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
18
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
19
Panitumumab Approved, Investigational Phase 2,Phase 1 339177-26-3 50070211
20
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
21
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
22
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
23
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
24
Pembrolizumab Approved Phase 2 1374853-91-4
25
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
26
Pentetic acid Approved Phase 2 67-43-6
27 Antineoplastic Agents, Immunological Phase 2,Phase 1
28 Protein Kinase Inhibitors Phase 2
29 ON 01910 Phase 2
30 Immunoglobulins Phase 2,Phase 1
31 Antibodies Phase 2,Phase 1
32 Vaccines Phase 2,Phase 1
33 Antibodies, Monoclonal Phase 2,Phase 1
34 Central Nervous System Depressants Phase 2
35 Neurotransmitter Agents Phase 2
36 Psychotropic Drugs Phase 2
37 Tranquilizing Agents Phase 2
38 Antimanic Agents Phase 2
39 Anticonvulsants Phase 2
40 GABA Agents Phase 2
41 taxane Phase 2
42
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
43
Fludarabine Approved Phase 1 75607-67-9, 21679-14-1 30751
44
nivolumab Approved Phase 1 946414-94-4
45
Ipilimumab Approved Phase 1 477202-00-9
46
Manganese Approved, Nutraceutical Phase 1 7439-96-5 27854
47 Antineoplastic Agents, Alkylating Phase 1
48 Antirheumatic Agents Phase 1
49 Antibodies, Bispecific Phase 1
50
Ethanol Approved 64-17-5 702

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
3 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
4 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
5 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
6 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
8 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
9 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
10 Vectibix for the Treatment of Anal Cancer Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
11 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
12 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
13 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
14 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
15 Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) Recruiting NCT03944252 Phase 2 Avelumab;Cetuximab
16 A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
17 Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
18 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
19 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
20 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
21 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Active, not recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
22 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
23 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
24 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
25 A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer Active, not recruiting NCT02797964 Phase 1, Phase 2 SRA737
26 Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) Not yet recruiting NCT03946358 Phase 2 Atezolizumab;UCPVax
27 A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Withdrawn NCT02857608 Phase 2 Lymphoseek
28 A Phase 1 Study in Participants With Advanced Cancer Completed NCT01115790 Phase 1 Prexasertib
29 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
30 Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer Recruiting NCT03386500 Phase 1 BMX-001
31 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
32 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02408861 Phase 1
33 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting NCT03894618 Phase 1 SL-279252
34 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Recruiting NCT03517488 Phase 1
35 ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Completed NCT02145416
36 Molecular Biology of Anal Cancer in HIV-Positive Patients Completed NCT00952874
37 Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor? Completed NCT03469596
38 Anal Dysplasia in Patients With Inflammatory Bowel Disease Completed NCT01653054 Not Applicable
39 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
40 Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients Recruiting NCT01877135
41 Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) Recruiting NCT03241680 Not Applicable
42 Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021 Not Applicable
43 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Active, not recruiting NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
44 Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men Active, not recruiting NCT02816879 Not Applicable
45 Seville Cohort of People Living With HIV at Risk for Anal Cancer Enrolling by invitation NCT03713229
46 Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma Not yet recruiting NCT03942900
47 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Not yet recruiting NCT03061435 Not Applicable
48 Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Terminated NCT02407561
49 Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer Withdrawn NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

42
Breast, Cervix, Lung, Lymph Node, Skin, Colon, Bone

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 120)
# Title Authors Year
1
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
2
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. ( 30415990 )
2019
3
Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. ( 30636052 )
2019
4
The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma. ( 30644029 )
2019
5
Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence. ( 30773194 )
2019
6
Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. ( 30788159 )
2019
7
Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. ( 31015125 )
2019
8
Early versus late salvage abdominoperineal resection for anal squamous cell carcinoma: Is there a difference in survival? ( 31055841 )
2019
9
The Management and Prevention of Anal Squamous Cell Carcinoma. ( 31099616 )
2019
10
Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )
2018
11
Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )
2018
12
Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )
2018
13
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )
2018
14
Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )
2018
15
Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )
2018
16
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )
2018
17
Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )
2018
18
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. ( 29466950 )
2018
19
The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. ( 29487716 )
2018
20
Anal squamous cell carcinoma - State of the art management and future perspectives. ( 29494827 )
2018
21
Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ( 29514401 )
2018
22
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. ( 30042063 )
2018
23
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. ( 30054279 )
2018
24
Oestrogen receptor can be expressed by normal and dysplastic anal squamous epithelia but only rarely by anal squamous cell carcinoma. ( 30062743 )
2018
25
Anal squamous cell carcinoma: are we improving outcomes? ( 30159994 )
2018
26
Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. ( 30194195 )
2018
27
ASO Author Reflections: The Role of Tumor Size in the Prognosis of Anal Squamous Cell Carcinoma: A Validation on the New American Joint Committee on Cancer Subclassification of Stage IIA and B. ( 30367300 )
2018
28
Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study. ( 30504412 )
2018
29
Multiple primary malignancies in patients with anal squamous cell carcinoma. ( 30505585 )
2018
30
Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis. ( 30603130 )
2018
31
Prognostic Significance of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Anal Squamous Cell Carcinoma: A Systematic Review and a Meta-Analysis. ( 30627062 )
2018
32
Chemotherapeutic Response and Survival for Patients With an Anal Squamous Cell Carcinoma and Low Hemoglobin Levels. ( 30630304 )
2018
33
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )
2017
34
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. ( 27852700 )
2017
35
The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )
2017
36
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )
2017
37
High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )
2017
38
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )
2017
39
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )
2017
40
Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )
2017
41
Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )
2017
42
Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )
2017
43
Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )
2017
44
Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )
2017
45
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )
2017
46
Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )
2017
47
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )
2016
48
Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )
2016
49
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )
2016
50
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )
2016

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 AKT1 CDKN2A MDM2 MLH1 TP53 TP73
2
Show member pathways
13.31 AKT1 CDKN2A MDM2 MLH1 TP53
3
Show member pathways
12.9 AKT1 APC MDM2 PIK3CA TP53
4
Show member pathways
12.88 AKT1 CDKN2A MDM2 PIK3CA TP53
5
Show member pathways
12.83 AKT1 CDKN2A MDM2 MLH1 TP53 TP73
6
Show member pathways
12.67 AKT1 CDKN2A MDM2 PIK3CA TP53 TP73
7
Show member pathways
12.65 AKT1 MDM2 PIK3CA TP53
8
Show member pathways
12.62 AKT1 APC CDKN2A MLH1 PIK3CA TP53
9
Show member pathways
12.61 AKT1 APC PIK3CA TP53 TP73
10
Show member pathways
12.61 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
11
Show member pathways
12.59 AKT1 CDKN2A MDM2 PIK3CA TP53
12
Show member pathways
12.54 AKT1 MDM2 PIK3CA TP53
13 12.53 AKT1 APC CDKN2A MDM2 MLH1 PIK3CA
14
Show member pathways
12.52 AKT1 CDKN2A MDM2 TP53
15
Show member pathways
12.48 AKT1 MDM2 PIK3CA TP53
16
Show member pathways
12.45 AKT1 APC PIK3CA TP53
17 12.43 APC CDKN2A MDM2 PIK3CA TP53
18 12.42 CDKN2A MDM2 MLH1 TP53 TP73
19
Show member pathways
12.38 AKT1 MDM2 PIK3CA TP53
20
Show member pathways
12.36 AKT1 PIK3CA TP53
21 12.34 AKT1 APC TP53
22
Show member pathways
12.34 AKT1 MDM2 PIK3CA TP53
23
Show member pathways
12.31 CDKN2A MDM2 TP53 TP73
24 12.3 APC CDKN2A MDM2 TP53
25 12.26 AKT1 APC CDKN2A PIK3CA TP53
26
Show member pathways
12.24 AKT1 PIK3CA TP53
27 12.23 AKT1 MDM2 PIK3CA TP53
28 12.23 CDKN2A MDM2 PIK3CA TP53
29
Show member pathways
12.19 AKT1 MDM2 TP53
30
Show member pathways
12.15 AKT1 MDM2 PIK3CA
31
Show member pathways
12.15 AKT1 MDM2 PIK3CA TP53
32 12.13 AKT1 APC MLH1 TP53
33
Show member pathways
12.11 AKT1 PIK3CA TP53
34 12.09 AKT1 MDM2 TP53
35
Show member pathways
12.08 AKT1 PIK3CA TP53
36 12.07 AKT1 MDM2 PIK3CA TP53
37
Show member pathways
12.06 AKT1 MDM2 PIK3CA
38 12.06 AKT1 CDKN2A MDM2 PIK3CA TP53
39 12.04 AKT1 PIK3CA TP53
40 12.04 AKT1 APC PIK3CA
41
Show member pathways
12.03 AKT1 MDM2 PIK3CA
42 11.99 CDKN2A MDM2 TP53
43
Show member pathways
11.99 AKT1 TP53 TP73
44
Show member pathways
11.98 AKT1 PIK3CA TP53
45 11.96 AKT1 PIK3CA TP53
46 11.95 APC MDM2 MLH1 TP53 TP73
47 11.93 AKT1 MDM2 PIK3CA TP53
48 11.91 CDKN2A MDM2 TP53
49 11.85 AKT1 PIK3CA TP53
50 11.85 AKT1 APC CDKN2A MDM2 TP53

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.5 AKT1 APC CDKN2A MDM2 PIK3CA TP53
2 nucleoplasm GO:0005654 9.17 AKT1 APC CDKN2A MDM2 MLH1 TP53

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.9 AKT1 CDKN2A TP53 TP73
2 cell cycle GO:0007049 9.86 CDKN2A MLH1 TP53 TP73
3 positive regulation of transcription, DNA-templated GO:0045893 9.85 AKT1 CDKN2A TP53 TP73
4 regulation of apoptotic process GO:0042981 9.82 AKT1 TP53 TP73
5 protein deubiquitination GO:0016579 9.81 APC MDM2 TP53
6 regulation of gene expression GO:0010468 9.79 MDM2 PIK3CA TP73
7 positive regulation of gene expression GO:0010628 9.71 AKT1 CDKN2A MDM2 TP53
8 protein kinase B signaling GO:0043491 9.65 AKT1 PIK3CA
9 protein sumoylation GO:0016925 9.65 CDKN2A MDM2
10 cellular response to hypoxia GO:0071456 9.65 AKT1 MDM2 TP53
11 cellular response to DNA damage stimulus GO:0006974 9.65 AKT1 APC MLH1 TP53 TP73
12 protein tetramerization GO:0051262 9.63 TP53 TP73
13 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 AKT1 PIK3CA
14 protein-containing complex assembly GO:0065003 9.63 APC MDM2 TP53
15 mismatch repair GO:0006298 9.62 MLH1 TP73
16 response to antibiotic GO:0046677 9.62 MDM2 TP53
17 cellular response to gamma radiation GO:0071480 9.61 MDM2 TP53
18 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.59 TP53 TP73
19 positive regulation of cell cycle arrest GO:0071158 9.58 TP53 TP73
20 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 APC CDKN2A
21 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.57 TP53 TP73
22 apoptotic mitochondrial changes GO:0008637 9.54 AKT1 CDKN2A
23 positive regulation of protein export from nucleus GO:0046827 9.52 MDM2 TP53
24 negative regulation of macroautophagy GO:0016242 9.51 AKT1 PIK3CA
25 replicative senescence GO:0090399 9.49 CDKN2A TP53
26 cell cycle arrest GO:0007050 9.46 APC CDKN2A TP53 TP73
27 anoikis GO:0043276 9.43 AKT1 PIK3CA
28 amyloid fibril formation GO:1990000 9.37 CDKN2A MDM2
29 positive regulation of apoptotic process GO:0043065 9.35 AKT1 APC CDKN2A TP53 TP73
30 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
31 regulation of signal transduction by p53 class mediator GO:1901796 8.92 AKT1 MDM2 TP53 TP73

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.72 AKT1 APC MDM2 TP53 TP73
2 ubiquitin protein ligase binding GO:0031625 9.61 APC MDM2 TP53
3 enzyme binding GO:0019899 9.56 AKT1 MDM2 MLH1 TP53
4 protein phosphatase 2A binding GO:0051721 9.4 AKT1 TP53
5 SUMO transferase activity GO:0019789 9.37 CDKN2A MDM2
6 p53 binding GO:0002039 9.33 MDM2 TP53 TP73
7 disordered domain specific binding GO:0097718 9.13 CDKN2A MDM2 TP53
8 protein kinase binding GO:0019901 9.02 AKT1 APC CDKN2A TP53 TP73

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....